Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors

International Journal of Geriatric Psychiatry

Volumn 28, Issue 12, 2013, Pages 1312-1317

  Richardson, Cassandra ^a   Gard, Paul R ^b   Klugman, Anthony ^c   Isaac, Mokhtar ^c   Tabet, Naji ^a,c  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

^c SUSSEX PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

acetylcholinesterase inhibitors; Alzheimer's disease; cholinergic anti inflammatory pathway; cytokines; inflammation

Indexed keywords

DONEPEZIL; GALANTAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; RIVASTIGMINE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LONG TERM CARE; MALE; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; SYNAPTIC TRANSMISSION;

ACETYLCHOLINESTERASE INHIBITORS; ALZHEIMER'S DISEASE; CHOLINERGIC ANTI-INFLAMMATORY PATHWAY; CYTOKINES; INFLAMMATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHOLINESTERASE INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALANTAMINE; HUMANS; INDANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; PHENYLCARBAMATES; PIPERIDINES; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887240923     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3966     Document Type: Article

References (34)

1. Akiyama H, Barger S, Barnum S, et al,. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421. (Pubitemid 30349107)
2. Araujo DM, Lapchak PA,. 1994. Induction of immune system mediators in the hippocampal formation in Alzheimers and Parkinsons diseases-selective effects on specific interleukins and interleukin receptors. Neuroscience 61: 745-754. (Pubitemid 24291917)
3. Banks WA,. 2005. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11: 973-984. (Pubitemid 40331299)
4. Chae CU, Lee RT, Rifai N, et al,. 2001. Blood pressure and inflammation in apparently healthy men. Hypertension 38: 399-403. (Pubitemid 34225673)
5. DeSimoni MG, Sironi M, Deluigi A, et al,. 1990. Intracerebroventricular injection of interleukin-1 induces high circulating levels of interleukin-6. J Exp Med 171: 1773-1778. (Pubitemid 20167565)
6. Devries HE, Kuiper J, Deboer AG, et al,. 1997. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 49: 143-155. (Pubitemid 27291032)
7. Faul F, Erdfelder E, Lang AG, et al,. 2007. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
8. Folstein MF, Folstein SE, McHugh PR,. 1975. Mini-mental state-practical method for grading cognitive state of patients for clinician. J Psychiatr Res 12: 189-198.
9. Fox C, Richardson K, Maidment ID, et al,. 2011. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 59: 1477-83.
10. Francis PT, Nordberg A, Arnold SE,. 2005. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 26: 104-111. (Pubitemid 40170173)
11. Gallowitsch-Puerta M, Tracey KJ,. 2005. Immunologic role of the cholinergic anti inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. In:, Steinman, RM,. (ed.) Human Immunology: Patient-Based Research. New York: New York Academy of Sciences.
12. Gambi F, Reale M, Iarlori C, et al,. 2004. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol 24: 314-321. (Pubitemid 38658040)
13. Griffin WST, Stanley LC, Ling C, et al,. 1989. Brain Interleukin-1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86: 7611-7615. (Pubitemid 19254506)
14. Hodkinson HM,. 1972. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1: 233-238.
15. Hofer S, Eisenbach C, Lukic IK, et al,. 2008. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med 36: 404-408. (Pubitemid 351158611)
16. Lanzrein AS, Johnston CM, Perry VH, et al,. 1998. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1 beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and III, and alpha(1)-antichymotrypsin. Alzheimer Dis Assoc Disord 12: 215-227. (Pubitemid 29154993)
17. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimers disease-report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34: 939-944. (Pubitemid 14076461)
18. Morimoto K, Horio J, Satoh H, et al,. 2011. Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing ad pathology. J Alzheim Dis 25: 59-76.
19. Nizri E, Hamra-Amitay Y, Sicsic C, et al,. 2006. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 50: 540-547.
20. Opal SM, DePalo VA,. 2000. Anti-inflammatory cytokines. Chest 117: 1162-1172. (Pubitemid 30228378)
21. Peeters ACTM, Netea MG, Janssen MCH, et al,. 2001. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 31: 31-36. (Pubitemid 32151119)
22. Pirttila T, Mehta PD, Frey H, et al,. 1994. Alpha(1)-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimers disease. Neurobiol Aging 15: 313-317.
23. Pollak Y, Gilboa A, Ben-Menachem O, et al,. 2005. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol 57: 741-745. (Pubitemid 40628864)
24. Pradhan AD, Manson JE, Rifai N, et al,. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334. (Pubitemid 32656163)
25. Reale M, Iarlori C, Gambi F, et al,. 2004. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 148: 162-171. (Pubitemid 38229569)
26. Rogers J, Webster S, Lue LF, et al,. 1996. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17: 681-686. (Pubitemid 26348868)
27. Romero LI, Kakucska I, Lechan RM, et al,. 1996. Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1 beta in rats. Am J Physiol Regul Integr Comp Physiol 270: R518-R524.
28. Shytle RD, Mori T, Townsend K, et al,. 2004. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89: 337-343. (Pubitemid 38495982)
29. Sinem F, Dildar K, Gokhan E, et al,. 2010. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res 7: 463-469.
30. Swardfager W, Lanctot K, Rothenburg L, et al,. 2010. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68: 930-941.
31. Tabet N,. 2006. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing 35: 336-338. (Pubitemid 43941799)
32. Tracey KJ,. 2002. The inflammatory reflex. Nature 420: 853-859. (Pubitemid 36019638)
33. Unger C, Svedberg MM, Schutte M, et al,. 2005. Effect of memantine on the alpha 7 neuronal nicotinic receptors, synaptophysin- and low molecular weight MAP-2 levels in the brain of transgenic mice over-expressing human acetylcholinesterase. J Neural Transm 112: 255-68. (Pubitemid 40179118)
34. Wood JA, Wood PL, Ryan R, et al,. 1993. Cytokine indexes in Alzheimers temporal cortex no changes in mature IL-1 beta to IL-1RA but increases in the associated acute-phase proteins IL-6, Alpha-2 macroglobulin and C-reactive protein. Brain Res 629: 245-252. (Pubitemid 23337798)